Cardiol Therapeutics Inc. (CRDL)

NASDAQ: CRDL · USD

$1.17

+0.03 (+2.6%)· Recorded snapshot

Market cap	138.3M
Net income (ttm)	-24M
EPS (ttm)	-$0.24
Shares out	116.8M
Volume	433,293
Beta	0.72

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -24M
EPS (ttm): -$0.24
Market cap: 138.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-190.2

P25 n/aP50 n/aP75 n/a

ROIC-124.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CRDL indicators

Market & fundamental data

Available fields

177

Groups with data

Currency

CAD

Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001702123
Company name	Cardiol Therapeutics Inc.
Country	Canada
Country code	US
CUSIP number	14161Y200
Earnings date	2026-11-12
Earnings time	amc
Employees	18
Employees change	12
Employees growth	200%
Enterprise value	$119.8M
Exchange	NASDAQ
Financial currency	CAD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	No
Is SPAC	No
ISIN number	CA14161Y2006
Last 10-K release date	2024-04-01
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$138.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$1.17
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CRDL
Website	https://www.cardiolrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.41%
FCF / EV yield	-14.77%
FCF yield	-12.74%
Industry forward P/E	13.86x
Industry P/E	173.47x
P/B ratio	7.96x
Price / tangible book value	7.96x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.3M
ROA	-90.92%
ROA (5Y)	-53.9%
ROCE	-148.81%
ROE	-190.18%
ROE (5Y)	-97.2%
ROIC	-124.2%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	1
Net income growth quarters	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-40,403
Depreciation and amortization	$6,551
EBIT	$-25.2M
EBITDA	$-25.2M
EPS	$-0.24
FCF per share	$-0.15
Financing cash flow	$22.3M
Free cash flow	$-17.2M
Free cash flow minus SBC	$-25.2M
Investing cash flow	$-39,941
Net borrowing	$-39,445
Net cash flow	$5.6M
Net income	$-24M
Operating cash flow minus SBC	$-25.1M
Operating income	$-25.2M
Stock-based compensation	$7.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.15
Debt / equity	0
Long-term assets	$-146,195
Long-term liabilities	$3,389
Net cash (debt)	$18.3M
Net cash / market cap	13.57%
Net cash growth	43.88%
Net debt / equity	-1.08
Piotroski F-Score	2
Property, plant and equipment	$92,924
Shareholders' equity	$16.9M
Tangible book value	$16.9M
Tangible book value per share	$0.15
Total assets	$20.7M
Total cash	$18.4M
Total debt	$75,345
Total liabilities	$3.8M
WACC	8.23%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$20.8M
Current liabilities	$3.7M
Current ratio	5.55
Net working capital	$-1.5M
Quick ratio	5.01
Working capital	$16.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-28.88%
Dividend yield	0%
Shareholder yield	-28.88%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.40
1D price change	2.63%
1M price change	-31.87%
1M total return	-31.87%
1W price change	1.3%
1W total return	1.3%
1Y price change	-4.51%
1Y return CAGR	-4.51%
1Y total return	-4.51%
20-day SMA	$1.22
200-day SMA	$1.30
3M price change	0.87%
3M total return	0.87%
3Y price change	38.69%
3Y return CAGR	11.52%
3Y total return	38.69%
50-day SMA	$1.65
50-day SMA vs 200-day SMA	50over200
52-week high	$2.34
52-week high date	2026-09-09
52-week low	$0.88
52-week low date	2025-12-01
5Y price change	-71.31%
5Y return CAGR	-22.1%
5Y total return	-71.31%
6M price change	-16.79%
6M total return	-16.79%
All-time high	$10.00
All-time high date	2019-02-25
All-time low	$0.45
All-time low date	2023-04-05
Average true range (ATR)	$0.08
Average volume	1.5M
Beta (5Y)	0.73
Change from 52-week high	-50%
Change from 52-week low	32.96%
Change from all-time high	-88.35%
Change from all-time low	158.89%
Change from open	2.63%
Day's gap	0%
Dollar volume	$506,953
High price	$1.17
Low price	$1.14
Monthly RSI	47.16
Open price	$1.14
Position in 52-week range	100%
Premarket change	1.75%
Premarket close	$1.14
Premarket price	$1.16
Previous close	$1.14
Price vs 150-day SMA	-16.61%
Price vs 20-day SMA	-4.27%
Price vs 200-day SMA	-10.52%
Price vs 50-day SMA	-29.52%
Relative volume	0.3
RSI	32.86
Sharpe ratio	0.16
Sharpe ratio (3Y)	0.56
Sharpe ratio (5Y)	0.04
Sortino ratio	0.34
Sortino ratio (3Y)	0.99
Sortino ratio (5Y)	0.13
Volume	433.3K
Weekly RSI	42.86
YTD price change	22.14%
YTD total return	22.14%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	92M
Float percentage	78.73%
Shares change (QoQ)	5.46%
Shares change (YoY)	28.88%
Shares held by insiders	3.03%
Shares held by institutions	13.13%
Shares outstanding	116.8M
Short % of float	3.34%
Short % of shares	2.63%
Short ratio	2.5 days

Deeper analysis on CRDL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CRDL report

Is a complete CRDL research report available?

No complete published report is available for Cardiol Therapeutics Inc. (CRDL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cardiol Therapeutics Inc. (CRDL)

Price

Financial snapshot

Fair-value bridge

Latest news · CRDL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CRDL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CRDL

Frequently asked questions